Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer

Journal of Urology

Volumn 169, Issue 2, 2003, Pages 517-523

  Han, Misop ^a   Partin, Alan W ^a   Zahurak, Marianna ^a   Piantadosi, Steven ^a   Epstein, Jonathan I ^a   Walsh, Patrick C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Neoplasms; Prognosis; Prostatectomy; Recurrence

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MALE GENITAL TRACT CANCER; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE CANCER; PROSTATE DISEASE; PROSTATECTOMY; TREATMENT OUTCOME;

EID: 0037304517     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)63946-8     Document Type: Article

References (23)

1. Pound, C. R., Partin, A. W., Eisenberger, M. A., Chan, D. W., Pearson, J. D. and Walsh, P. C.: Natural history of progression after PSA elevation following radical prostatectomy. JAMA, 281: 1591, 1999
2. Pound, C. R., Partin, A. W., Epstein, J. J. and Walsh, P. C.: Prostate-specific antigen after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am, 24: 395, 1997
3. Catalona, W. J. and Smith, D. S.: 5-Year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol, 152: 1837, 1994
4. Catalona, W. J. and Smith, D. S.: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol, 160: 2428, 1998
5. Ohori, M., Goad, J. R., Wheeler, T. M., Eastham, J. A., Thompson, T. C. and Scardino, P. T.: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol, 152: 1843, 1994
6. Trapasso, J. G., deKernion, J. B., Smith, R. B. and Dorey, F.: The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol, 152: 1821, 1994
7. Zincke, H., Oesterling, J. E., Blute, M. L., Bergstralh, E. J., Myers, R. P. and Barrett, D. M.: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol, 152: 1850, 1994
8. Han, M., Partin, A. W., Pound, C. R., Epstein, J. I. and Walsh, P. C.: Long term biochemical disease-free and cancer-specific survival following anatomic radical retropubic prostatectomy: the 15-year Johns Hopkins experience. In: Urologic Clinics of North America. Edited by H. Lepor. Philadelphia: W. B. Saunders Co., pp. 555-565, 2001
9. Han, M., Partin, A. W., Piantadosi, S., Epstein, J. I. and Walsh, P. C.: Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer. J Urol, 166: 416, 2001
10. Beahrs, O. H., Henson, D. E., Hutter, R. V. P. and Myers, M. H.: American Joint Committee on Cancer Staging Manual, 4th ed. Philadelphia: J. B. Lippincott Co., pp. 181-186, 1992
11. Partin, A. W., Piantadosi, S., Sanda, M. G., Epstein, J. I., Marshall, F. F., Mohler, J. L. et al: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology, 45: 831, 1995
12. Partin, A. W., Pound, C. R., Clemens, J. Q., Epstein, J. I. and Walsh, P. C.: Serum PSA after anatomic radical prostatectomy. The Johns Hopkins experience after 10 years. Urol Clin North Am, 20: 713, 1993
13. Kaplan, E. L. and Meier, P.: Nonparametric estimation from incomplete observations. J Am Stat Assoc, 53: 457, 1958
14. Cox, D. R.: Regression models and life-tables. J R Stat Soc Ser B, 34: 187, 1972
15. Reiner, W. G. and Walsh, P. C.: An anatomical approach to the surgical management of the dorsal vein and Santorini's plexus during radical retropubic surgery. J Urol, 121: 198, 1979
16. Walsh, P. C. and Donker, P. J.: Impotence following radical prostatectomy: insight into etiology and prevention. J Urol, 128: 492, 1982
17. Stanford, J. L., Stephenson, R. A., Coyle, L. M., Carol Kosary, M. A., Cerhan, J., Correa, R. et al: Prostate Cancer Trends 1973-1995, SEER Program. Bethesda: National Institutes of Health, National Cancer Institute, 1999
18. Roberts, W. W., Bergstralh, E. J., Blute, M. L., Slezak, J. M., Carducci, M., Han, M. et al: Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology, 57: 1033, 2001
19. Kattan, M. W., Eastham, J. A., Stapleton, A. M., Wheeler, T. M. and Scardino, P. T.: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst, 90: 766, 1998
20. Kattan, M. W., Wheeler, T. M. and Scardino, P. T.: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol, 17: 1499, 1999
21. Amling, C. L., Blute, M. L., Bergstralh, E. J., Seay, T. M., Slezak, J. and Zincke, H.: Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol, 164: 101, 2000
22. Yang, X. J., Lecksell, K., Potter, S. R. and Epstein, J. I.: Significance of small foci of Gleason score 7 or greater prostate cancer on needle biopsy. Urology, 54: 528, 1999
23. Partin, A. W., Kattan, M. W., Subong, E. N., Walsh, P. C., Wojno, K. J., Oesterling, J. E. et al: Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA, 277: 1445, 1997